
























# Pharmaceuticals —






## Pipeline Overview and Progress






July 25, 2025 –  
Investor Relations
















# Pharmaceuticals – Pipeline Overview<sup>1</sup> (as of July 25, 2025)

Phase I
<b>DGKzeta Inhibitor</b> (BAY 2965501)  ●
<b>Lanerkitug</b> (CCR8 Ab) (BAY 3375968)  ●
<b>VVD KEAP1 Act</b> (VVD-130037 aka <i>NRF2 Inh</i> , BAY 3605349)  ●
<b>DGKalpha Inh</b> (BAY 2862789)  ●
<b>225Ac-Pelgifatamab</b> (BAY 3546828)  ●
<b>VVD STAT3 Inhibitor</b> (VVD-130850, BAY 3630914)  ●
<b>225Ac-PSMA-Trillium</b> (BAY 3563254)  ●
<b>SOS1 Inhibitor</b> (BAY 3498264)  ●
<b>PRMT5 Inhibitor</b> (BAY 3713372)  ●
<b>VVD RAS-PI3K Inhibitor</b> (VVD-159642, BAY 3674171)  ●
<b>225Ac-GPC3</b> (BAY 3547926)  ●
<b>VVD WRN Inhibitor</b> (VVD-214)  ●
<b>SEMA 3a</b> (BAY 3401016)  ●
<b>Dual FIIa/Xa Inhibitor</b> (BAY 3389934)  ●
<b>GIRK4 Inhibitor</b> (BAY 3670549) ●
<b>Bemdaneprocel</b> (Parkinson's Disease Cell Therapy) (BRT-DA01)  ●
<b>Multiple System Atrophy rAAV Gene Therapy</b> (AB-1005 aka AAV2-GDNF-MSA)  ●
<b>Pompe Disease rAAV Gene Therapy</b> (ACTUS-101)  ●
<b>LGMD2I/R9 rAAV Gene Therapy</b> (AB-1003 aka LION-101)  ●
<b>GPR84 Antagonist</b> (BAY 3178275)  ●
<b>BAY 2701250</b>  ●
<b>Primary Photoreceptor Diseases Cell Therapy</b> (BRT-OpCT-001)  ●

Phase II
<b>Sevabertinib</b> (HER2/mEGFR Inhibitor) (BAY 2927088)  ○ # Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (panSOHO)
<b>Congestive Heart Failure rAAV Gene Therapy</b> (AB-1002)  ● # Congestive Heart Failure (GenePHIT)
<b>Anti-a2AP</b> (BAY 3018250)  ● # Acute Ischemic Stroke; Pulmonary Embolism (SIRIUS)
<b>Nurandociguat</b> (sGC Activator Oral) (BAY 3283142)  ● # Chronic Kidney Disease (ALPINE-1)
<b>Parkinson's Disease rAAV Gene Therapy</b> (AB-1005)  ● # Parkinson's Disease (REGENERATE-PD)

Phase III
<b>Darolutamide</b> (AR Inhibitor)  ○ # Adjuvant Prostate Cancer (DASL-HiCaP) # Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP)
<b>Sevabertinib</b> (HER2/mEGFR Inhibitor)  ● # Advanced Non-small Cell Lung Cancer with HER2 Activating Mutations, 1L (SOHO-02)
<b>Finerenone</b> (MR Antagonist)  ○ # Non-diabetic Chronic Kidney Disease (FIND-CKD) # Chronic Kidney Disease in Type 1 Diabetes (FINE-ONE)
<b>Vericiguat</b> (sGC Stimulator)  ○ # Heart Failure (HFrEF) (VICTOR <sup>2</sup> )
<b>Asundexian</b> (FXIa Inhibitor)  ● # 2° Stroke Prevention (OCEANIC-STROKE)

Submissions
<b>Darolutamide</b> (AR Inhibitor)  ○ # CN: Prostate Cancer (mHSPC)
<b>Sevabertinib</b> (HER2/mEGFR Inhibitor)  ● # US, CN: HER2-mut NSCLC 2L
<b>Finerenone</b> (MR Antagonist)  ○ # EU, CN, JP: Heart Failure (HFmr/pEF)
<b>Elinzanetant</b> (Neurokinin-1,3 Rec Antagonist)  ● # US, EU: Vasomotor Symptoms
<b>Aflibercept 8mg</b> (VEGF-Inhibitor)  ○ # EU, JP: Retinal Vein Occlusion
<b>Gadoquatrane</b> (High Relaxivity Contrast Agent)  ● # US, EU, JP: Magnetic Resonance Imaging







	Oncology
	Cardiovascular+ <sup>3</sup>
	Neurology & Rare Diseases
	Immunology
	Others
	New molecular entity
	Life cycle management

 Protein Therapeutics
  Cell Therapy
  Contrast Agent
  Genetic Medicine
  Radioisotope Therapy
  Small Molecule

<sup>1</sup> Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit  
<sup>2</sup> Conducted by Merck & Co <sup>3</sup> Including Precision Cardiovascular, Nephrology & Acute Care



# Pharmaceuticals – Pipeline Details Phase III<sup>1</sup> (as of July 25, 2025)






Therapeutic Area	Candidate Medication	Modality	Indication	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Oncology	Darolutamide (AR Inhibitor)		Adjuvant Prostate Cancer ( <i>DASL-HiCaP</i> )	<a href="#">NCT04136353</a>	Q1 2028	Study ongoing
			Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy ( <i>ARASTEP</i> )	<a href="#">NCT05794906</a>	Q3 2027	Study ongoing
	Sevabertinib (HER2/mEGFR Inhibitor)		Advanced Non-small Cell Lung Cancer with HER2 Activating Mutations, 1L ( <i>SOHO-02</i> )	<a href="#">NCT06452277</a>	Q2 2026	Study ongoing
Cardiovascular+ <sup>3</sup>	Finerenone (MR Antagonist)		Non-diabetic Chronic Kidney Disease ( <i>FIND-CKD</i> )	<a href="#">NCT05047263</a>	Q1 2026	Study ongoing
			Chronic Kidney Disease in Type 1 Diabetes ( <i>FINE-ONE</i> )	<a href="#">NCT05901831</a>	Q3 2025	Study ongoing
	Vericiguat (sGC Stimulator)		Heart Failure (HFrEF) ( <i>VICTOR<sup>2</sup></i> )	<a href="#">NCT05093933</a>	Q4 2024	Study completed
	Asundexian (FXIa Inhibitor)		2° Stroke Prevention ( <i>OCEANIC-STROKE</i> )	<a href="#">NCT05686070</a>	Q4 2025	Study ongoing
Others	Gadoquatrane (High Relaxivity Contrast Agent)		Magnetic Resonance Imaging ( <i>QUANTI-CNS, QUANTI-OB</i> )	<a href="#">NCT05915702</a> <a href="#">NCT05915728</a>	Q2 2024 Q2 2024	Studies completed

<sup>1</sup> Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit <sup>2</sup> Conducted by Merck & Co

<sup>3</sup> Including Precision Cardiovascular, Nephrology & Acute Care



# Pharmaceuticals – Pipeline Details Phase II<sup>1</sup> (as of July 25, 2025)

Therapeutic Area	Candidate Medication	Modality	Indication	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Oncology	Sevabertinib (HER2/mEGFR Inhibitor) (BAY 2927088)		Metastatic or Unresectable Solid Tumors With HER2-activating Mutations ( <i>panSOHO</i> )	<a href="#">NCT06760819</a>	Q1 2027	Study ongoing
Cardiovascular+ <sup>2</sup>	Congestive Heart Failure rAAV Gene Therapy (AB-1002)		Congestive Heart Failure ( <i>GenePHIT</i> )	<a href="#">NCT05598333</a>	Q4 2026	Study ongoing
	Anti-α2AP (BAY 3018250)		Acute Ischemic Stroke; Pulmonary Embolism ( <i>SIRIUS</i> )	<a href="#">NCT06149520</a>	Q4 2025	Study ongoing
	Nurandociguat (sGC Activator Oral) (BAY 3283142)		Chronic Kidney Disease ( <i>ALPINE-1</i> )	<a href="#">NCT06522997</a>	Q1 2026	Study ongoing
Neurology & Rare Diseases	Parkinson's Disease rAAV Gene Therapy (AB-1005)		Parkinson's Disease ( <i>REGENERATE-PD</i> )	<a href="#">NCT06285643</a>	Q4 2027	Study ongoing

<sup>1</sup> Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit <sup>2</sup> Including Precision Cardiovascular, Nephrology & Acute Care



Protein Therapeutics



Cell Therapy



Contrast Agent



Genetic Medicine



Radionuclide Therapy
























Small Molecule





# Pharmaceuticals – Pipeline Details Phase I<sup>1</sup> (as of July 25, 2025)































Therapeutic Area	Candidate Medication	Modality	Indication	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Oncology	DGKzeta Inhibitor (BAY 2965501)		Advanced Solid Tumors	<a href="#">NCT05614102</a>	Q2 2027	Study ongoing
	Lanerkitug (CCR8 Ab) (BAY 3375968)		Advanced Solid Tumors	<a href="#">NCT05537740</a>	Q4 2026	Study ongoing
	VVD KEAP1 Act (VVD-130037 aka NRF2 Inh, BAY 3605349)		Advanced Solid Tumors	<a href="#">NCT05954312</a>	Q4 2027	Study ongoing
	DGKalpha Inhibitor (BAY 2862789)		Advanced Solid Tumors	<a href="#">NCT05858164</a>	Q3 2025	Study ongoing
	225Ac-Pelgifatamab (BAY 3546828)		Advanced Prostate Cancer	<a href="#">NCT06052306</a>	Q2 2027	Study ongoing
	VVD STAT3 Inhibitor (VVD-130850, BAY 3630914)		Advanced Solid and Hematologic Tumors	<a href="#">NCT06188208</a>	Q4 2027	Study ongoing
	225Ac-PSMA-Trillium (BAY 3563254)		Advanced Prostate Cancer	<a href="#">NCT06217822</a>	Q2 2027	Study ongoing
	SOS1 Inhibitor (BAY 3498264)		Advanced Solid Cancers	<a href="#">NCT06659341</a>	Q1 2027	Study ongoing
	PRMT5 Inhibitor (BAY 3713372)		MTAP-deleted Solid Tumors	<a href="#">NCT06914128</a>	Q2 2029	Study ongoing
	VVD RAS-PI3K Inhibitor (VVD-159642, BAY 3674171)		Advanced Solid Tumors	<a href="#">NCT06804824</a>	Q3 2027	Study ongoing
	225Ac-GPC3 (BAY 3547926)		Advanced Liver Cancer	<a href="#">NCT06764316</a>	Q3 2030	Study ongoing
	VVD WRN Inhibitor (VVD-214)		Advanced Solid Tumors	<a href="#">NCT06004245</a>	Q2 2027	Study ongoing
Cardiovascular+ <sup>2</sup>	SEMA 3a (BAY 3401016)		Alport Syndrome	n/a	Q3 2025	Study ongoing
	Dual FIIa/Xa Inhibitor (BAY 3389934)		Anti-coagulation	<a href="#">NCT06854640</a>	Q1 2026	Study ongoing
	GIRK4 Inhibitor (BAY 3670549)	Undisclosed	Atrial fibrillation	n/a	Q1 2026	Study ongoing
Neurology / Rare Diseases	Bemdaneprocel (Parkinson's Disease Cell Therapy) (BRT-DA01)		Parkinson's Disease	<a href="#">NCT04802733</a>	Q2 2023	Study completed
	Multiple System Atrophy rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-MSA)		Multiple System Atrophy	<a href="#">NCT04680065</a>	Q3 2026	Study ongoing
	Pompe Disease rAAV Gene Therapy (ACTUS-101)		Pompe Disease	<a href="#">NCT03533673</a>	Q3 2022	Study ongoing
	LGMD2I/R9 rAAV Gene Therapy (AB-1003 aka LION-101)		Limb Girdle Muscular Dystrophy	<a href="#">NCT05230459</a>	Q4 2028	Study ongoing
Others	GPR84 Antagonist (BAY 3178275)		Diabetic Neuropathic Pain	n/a	Q1/2024	Study completed
	BAY 2701250		Pulmonary Hypertension	<a href="#">NCT06048120</a>	Q2 2025	Study completed
	Primary Photoreceptor Diseases Cell Therapy (BRT-OpCT-001)		Primary Photoreceptor Disease	<a href="#">NCT06789445</a>	Q3 2029	Study ongoing

<sup>1</sup> Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit <sup>2</sup> Including Precision Cardiovascular, Nephrology & Acute Care

\*Bayer acquired Noria and PSMA Therapeutics in 2021



# Pharmaceuticals – Pipeline Details Oncology<sup>1</sup> (as of July 25, 2025)

Candidate medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Darolutamide (AR Inhibitor)	Adjuvant Prostate Cancer (DASL-HiCaP)					<a href="#">NCT04136353</a>	Q1 2028	Study ongoing
	Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP)					<a href="#">NCT05794906</a>	Q3 2027	Study ongoing
Sevabertinib (HER2/mEGFR Inhibitor) (BAY 2927088)	Advanced Non-small Cell Lung Cancer with HER2 Activating Mutations, 1L (SOHO-02)					<a href="#">NCT06452277</a>	Q2 2026	Study ongoing
	Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (panSOHO)					<a href="#">NCT06760819</a>	Q1 2027	Study ongoing
DGKzeta Inhibitor (BAY 2965501)	Advanced Solid Tumors					<a href="#">NCT05614102</a>	Q2 2027	Study ongoing
Lanerkitug (CCR8 Ab) (BAY 3375968)	Advanced Solid Tumors					<a href="#">NCT05537740</a>	Q4 2026	Study ongoing
VVD KEAP1 Act (VVD-130037 aka NRF2 Inh, BAY 3605349)	Advanced Solid Tumors					<a href="#">NCT05954312</a>	Q4 2027	Study ongoing
DGKalpha Inh (BAY 2862789)	Advanced Solid Tumors					<a href="#">NCT05858164</a>	Q3 2025	Study ongoing
225Ac-Pelgifatamab (BAY 3546828)	Advanced Prostate Cancer					<a href="#">NCT06052306</a>	Q2 2027	Study ongoing
VVD STAT3 Inhibitor (VVD-130850, BAY 3630914)	Advanced Solid and Hematologic Tumors					<a href="#">NCT06188208</a>	Q4 2027	Study ongoing
225Ac-PSMA-Trillium (BAY 3563254)	Advanced Prostate Cancer					<a href="#">NCT06217822</a>	Q2 2027	Study ongoing
SOS1 Inhibitor (BAY 3498264)	Advanced Solid Cancers					<a href="#">NCT06659341</a>	Q1 2027	Study ongoing
PRMT5 Inhibitor (BAY 3713372)	MTAP-deleted Solid Tumors					<a href="#">NCT06914128</a>	Q2 2029	Study ongoing
VVD RAS-PI3K Inhibitor (VVD-159642, BAY 3674171)	Advanced Solid Tumors					<a href="#">NCT06804824</a>	Q3 2027	Study ongoing
225Ac-GPC3 (BAY 3547926)	Advanced Liver Cancer					<a href="#">NCT06764316</a>	Q3 2030	Study ongoing
VVD WRN Inhibitor (VVD-214)	Advanced Solid Tumors					<a href="#">NCT06004245</a>	Q2 2027	Study ongoing

<sup>1</sup> Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit

<sup>6</sup> \*Bayer acquired Noria and PSMA Therapeutics in 2021

/// Bayer Pharmaceuticals /// Pipeline Overview July 25, 2025



Protein Therapeutics



Cell Therapy



Contrast Agent



Genetic Medicine











Radionuclide Therapy



Small Molecule



# Pharmaceuticals – Pipeline Details Cardiovascular+<sup>1,3</sup> (as of July 25, 2025)











Candidate Medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Finerenone (MR Antagonist)	Non-diabetic CKD ( <i>FIND-CKD</i> )		<div><div></div></div>			<a href="#">NCT05047263</a>	Q1 2026	Study ongoing
	CKD in Type 1 Diabetes ( <i>FINE-ONE</i> )		<div><div></div></div>			<a href="#">NCT05901831</a>	Q3 2025	Study ongoing
Vericiguat (sGC Stimulator)	Heart Failure (HFrEF) ( <i>VICTOR<sup>2</sup></i> )		<div><div></div></div>			<a href="#">NCT05093933</a>	Q4 2024	Study completed
Asundexian (FXIa Inhibitor) (BAY 2433334)	2° Stroke Prevention ( <i>OCEANIC-STROKE</i> )		<div><div></div></div>			<a href="#">NCT05686070</a>	Q4 2025	Study ongoing
Congestive Heart Failure rAAV Gene Therapy ( <i>AB-1002</i> )	Congestive Heart Failure ( <i>GenePHIT</i> )		<div><div></div></div>			<a href="#">NCT05598333</a>	Q4 2026	Study ongoing
Anti-a2AP (BAY 3018250)	Acute Ischemic Stroke; Pulmonary Embolism ( <i>SIRIUS</i> )		<div><div></div></div>			<a href="#">NCT06149520</a>	Q4 2025	Study ongoing
Nurandociguat (sGC Act. Oral) (BAY 3283142)	Chronic Kidney Disease (CKD)		<div><div></div></div>			<a href="#">NCT06522997</a>	Q1 2026	Study ongoing
SEMA 3a (BAY 3401016)	Alport Syndrome		<div><div></div></div>			n/a	Q3 2025	Study ongoing
Dual FIIa/Xa Inhibitor (BAY 3389934)	Anti-coagulation		<div><div></div></div>			<a href="#">NCT06854640</a>	Q1 2026	Study ongoing
GIRK4 Inhibitor (BAY 3670549)	Atrial fibrillation	Undisclosed	<div><div></div></div>			n/a	Q1 2026	Study ongoing

 Protein Therapeutics
  Cell Therapy
  Contrast Agent
  Genetic Medicine
  Radionuclide Therapy
  Small Molecule

<sup>1</sup> Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit <sup>2</sup> Conducted by Merck & Co <sup>3</sup> Including Precision Cardiovascular, Nephrology & Acute Care



# Pharmaceuticals – Pipeline Details Neurol./Rare Dis.<sup>1</sup> (as of July 25, 2025)









Candidate Medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
<b>Parkinson's Disease rAAV Gene Therapy</b> (AB-1005)	Parkinson's Disease					<a href="https://clinicaltrials.gov/ct2/show/study/NCT06285643">NCT06285643</a>	Q4 2027	Study ongoing
<b>Bemdaneprocel</b> (Parkinson's Disease Cell Therapy) (BRT-DA01)	Parkinson's Disease					<a href="https://clinicaltrials.gov/ct2/show/study/NCT04802733">NCT04802733</a>	Q2 2023	Study completed
<b>Multiple System Atrophy rAAV Gene Therapy</b> (AB-1005 aka AAV2-GDNF-MSA)	Multiple System Atrophy					<a href="https://clinicaltrials.gov/ct2/show/study/NCT04680065">NCT04680065</a>	Q3 2026	Study ongoing
<b>Pompe Disease rAAV Gene Therapy</b> (ACTUS-101)	Pompe Disease					<a href="https://clinicaltrials.gov/ct2/show/study/NCT03533673">NCT03533673</a>	Q3 2022	Study ongoing
<b>LGMD2I/R9 rAAV Gene Therapy</b> (AB-1003 aka LION-101)	Limb-Girdle Muscular Dystrophy 2i					<a href="https://clinicaltrials.gov/ct2/show/study/NCT05230459">NCT05230459</a>	Q4 2028	Study ongoing

<sup>1</sup> Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit





# Pharmaceuticals – Pipeline Details Others<sup>1</sup> (as of July 25, 2025)

Candidate Medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
<b>Gadoquatrane</b> (High Relaxivity Contrast Agent, HRCA)	<b>Magnetic Resonance Imaging</b> ( <i>QUANTI-CNS, QUANTI-OB</i> )					<a href="#">NCT05915702</a> <a href="#">NCT05915728</a>	<b>Q2 2024</b> <b>Q2 2024</b>	Studies completed
<b>GPR84 Antagonist</b> ( <i>BAY 3178275</i> )	<b>Diabetic Neuropatic Pain</b>					n/a	<b>Q1 2024</b>	Study completed
<b>BAY 2701250</b>	<b>Pulmonary Hypertension</b>					<a href="#">NCT06048120</a>	<b>Q2 2025</b>	Study completed
<b>Primary Photoreceptor Diseases Cell Therapy</b> ( <i>BRT-OpCT-001</i> )	<b>Primary Photoreceptor Disease</b>					<a href="#">NCT06789445</a>	<b>Q3 2029</b>	Study ongoing

<sup>1</sup> Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit <sup>2</sup> Phase II pilot study on sleep disturbances associated with menopause